Clinical evaluation of methylprednisolone combined with high-flow nasal cannula oxygen therapy in the treatment of COPD patients with respiratory failure
HE Xiaohua
ZHU Qinghua
FU Junkai
Abstract：Objective To observe the efficacy of methylprednisolone combined with high-flow nasal cannula(HFNC)oxygen therapy in chronic obstructive pulmonary disease(COPD)patients with respiratory failure.Methods A retrospective cohort study design was adopted.Clinical data of 120 COPD patients with respiratory failure who met the inclusion and exclu-sion criteria were extracted from the electronic medical record system of Yiwu Central Hospital from July 2024 to April 2025.Patients were naturally divided into two groups according to the treatment regimens recorded in medical records.Data were independently extracted and quality-checked by two researchers,with a Cohen's kappa coefficient of 0.85.The conventional treatment group(n=60)received conventional anti-infection treatment,assisted PDCA(Plan-Do-Check-Act)rehabilitation,and HFNC as recorded in medical records,while the methylprednisolone group(n=60)received additional methylprednisolone so-dium succinate on the basis of the conventional treatment group.Arterial blood gas indicators,inflammatory markers,improve-ment in dyspnea,and adverse reactions were compared between the two groups.Results After treatment,arterial partial pres-sure of oxygen and oxygen saturation in the methylprednisolone group((72.85±6.13)mmHg,(91.20±4.13)%,respectively)were higher than those in the conventional treatment group((69.98±6.06)mmHg,(89.23±4.54)%),respectively),and arterial partial pressure of carbon dioxide in the methylprednisolone group((42.87±5.19)mmHg)was lower than that in the conventional treat-ment group((45.24±5.38)mmHg)(t=2.579,2.486,2.456,all P<0.05).The levels of C-reactive protein,procalcitonin,and serum amyloid A in the methylprednisolone group((7.38±2.15)mg/L,(0.54±0.15)ng/L,(27.65±6.13)mg/L,respectively)were lower than those in the conventional treatment group((9.75±2.27)mg/L,(0.81±0.30)ng/L,(30.81±7.20)mg/L,respectively)(t=5.872,6.235,2.589,all P<0.05).The dyspnea index score in the methylprednisolone group((1.22±0.50)points)was lower than that of the conventional treatment group((1.80±0.62)points)(t=5.641,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(10.00%(6/60)vs 5.00%(3/60))(χ2=1.081,P=0.298).Conclusion The combination of methylprednisolone and HFNC therapy can improve oxygenation,reduce inflammatory status and alleviate dyspnea,without increasing the risk of adverse reactions in COPD patients with respiratory failure.
Keywords：chronic obstructive pulmonary diseaserespiratory failuremethylprednisolonehigh-flow nasal cannula oxygen therapyretrospective cohort study
Publication Date：2026-03-25
Online Publishing Date：2026-04-07(First online date of this platform, not the publication date of the document)
Pages：5( 363-367 )